For Healthcare Professionals Outside the US

For patients with BRAF V600 mutation–positive unresectable or metastatic melanoma

For patients with BRAF V600 mutation–positive advanced non-small cell lung cancer (NSCLC)

Adverse reactions may be managed with dose modifications1,2

  • If treatment-related toxicities occur with Tafinlar + Mekinist, then the doses of both treatments should be simultaneously reduced, interrupted, or discontinued in most cases1,2
  • Dose reduction of Tafinlar only or Mekinist only is recommended for management of certain adverse reactions1,2
  • Dose modifications or interruptions are not recommended for cutaneous squamous cell carcinoma or new primary melanoma1,2
  • Refer to the Tafinlar and Mekinist summaries of product characteristics (SmPCs) for additional information on adverse reaction management1,2

Dose modification schedule based on the grade of any adverse reaction

Treatment modification.

Dose modification schedule for Tafinlar and Mekinist.

Monotherapy or in combination with Mekinist.
In combination with Tafinlar.

References: 1. Tafinlar Summary of Product Characteristics. Novartis Pharmaceuticals Corp; 2017. 2. Mekinist Summary of Product Characteristics. Novartis Pharmaceuticals Corp; 2017.